Last reviewed · How we verify
FX06
At a glance
| Generic name | FX06 |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- FX06 to Rescue Acute Respiratory Distress Syndrome During Covid-19 Pneumonia (PHASE2)
- Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FX06 CI brief — competitive landscape report
- FX06 updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI